Back to top
more

TransMedics Group (TMDX)

(Delayed Data from NSDQ)

$120.55 USD

120.55
1,776,330

+1.58 (1.33%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $120.51 -0.04 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?

by Zacks Equity Research

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.

Zacks Equity Research

Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.

Zacks Equity Research

Henry Schein (HSIC) Gears Up for Q1 Earnings: Factors to Note

by Zacks Equity Research

Henry Schein's (HSIC) first-quarter 2024 results are likely to indicate a strong sales recovery post last year's cybersecurity incident.

Zacks Equity Research

What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?

by Zacks Equity Research

Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.

Zacks Equity Research

What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?

by Zacks Equity Research

IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

Zacks Equity Research

CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

The strength of a diversified enterprise, along with robust operational execution, is expected to be reflected in CVS Health's (CVS) first-quarter 2024 results.

Zacks Equity Research

Labcorp (LH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.

Zacks Equity Research

TransMedics (TMDX) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

TransMedics (TMDX) reachead $91.82 at the closing of the latest trading day, reflecting no change compared to its last close.

Zacks Equity Research

Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.

Zacks Equity Research

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Nalak Das headshot

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zacks Equity Research

Strength Seen in Edwards Lifesciences (EW): Can Its 6.2% Jump Turn into More Strength?

by Zacks Equity Research

Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Why TransMedics (TMDX) Stock Might be a Great Pick

by Zacks Equity Research

TransMedics (TMDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Here's What Key Metrics Tell Us About TransMedics (TMDX) Q3 Earnings

by Zacks Equity Research

The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?

by Zacks Equity Research

Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant

by Zacks Equity Research

TransMedics' (TMDX) acquisition of Summit Aviation is likely to help establish TransMedics Aviation, the first integrated national provider of air logistics dedicated exclusively to organ transplantation.

Zacks Equity Research

TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of 80% and 25.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Paragon 28, Inc. (FNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -44.44% and 2.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -10.71% and 8.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of 68% and 19.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

TransMedics (TMDX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in TransMedics (TMDX): Can Its 12.3% Jump Turn into More Strength?

by Zacks Equity Research

TransMedics (TMDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.